There are currently 582 clinical trials in Omaha, Nebraska looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Nebraska Medical Center, Creighton University Medical Center, Nebraska Methodist Hospital and Alegent Health Bergan Mercy Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
NCT05076942
Recruiting
Vulvar cancer patients with SN-metastasis \> 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/27/2023
Locations: Nebraska Methodist Hospital, Omaha, Nebraska
Conditions: Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases
Register for Updates
Reading Outcomes in Children With Vestibular Loss
NCT05414903
Recruiting
Vestibular loss can co-occur with hearing loss causing dual sensory deficits. This project examines vestibular loss as a contributing factor to reading difficulties for children with hearing loss, where previously only the effects of hearing loss and subsequent language difficulties have been considered. These results are expected to influence the identification and habilitation of vestibular loss in children with hearing loss.
Gender:
ALL
Ages:
Between 8 years and 14 years
Trial Updated:
07/25/2023
Locations: Boys Town National Research Hospital, Omaha, Nebraska
Conditions: Vestibular Disorder, Hearing Loss, Sensorineural
Register for Updates
Canadian-American Spinal Cord Perfusion Pressure and Biomarker Study
NCT03911492
Recruiting
This multicenter study will enroll 100 patients with acute traumatic cervical and thoracic SCI who have a lumbar intrathecal catheter inserted within 24 hours of their injury. The lumbar intrathecal catheter will be inserted pre-operatively for the measurement of ITP and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between MAP and the ITP. There are two important distinct yet related objectives in this prospective interventional study. 1. Deter... Read More
Gender:
ALL
Ages:
17 years and above
Trial Updated:
06/30/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Acute Spinal Cord Injury, Acute Spinal Paralysis, Spinal Cord Injuries, SPINAL Fracture
Register for Updates
Vocal Emotion Communication With Cochlear Implants
NCT05486637
Recruiting
Patients with hearing loss who use cochlear implants (CIs) show significant deficits and strong unexplained intersubject variability in their perception and production of spoken emotions in speech. This project will investigate the hypothesis that "cue-weighting", or how patients utilize the different acoustic cues to emotion, accounts for significant variance in emotional communication with CIs. The results will focus on children with CIs, but parallel measures in postlingually deaf adults with... Read More
Gender:
ALL
Ages:
Between 6 years and 80 years
Trial Updated:
06/07/2023
Locations: Boys Town National Research Hospital, Omaha, Nebraska
Conditions: Cochlear Hearing Loss
Register for Updates
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Breast Cancer
Register for Updates